IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
复制标题
DOI：
10.1182/blood-2014-12-615757
复制
发表时间：
2015-05-28
期刊：
影响因子：
20.3
通讯作者：
Grupp, Stephan A.
中科院分区：
文献类型：
--
作者：
Pulsipher, Michael A.;Carlson, Chris;Grupp, Stephan A.
急性淋巴细胞白血病（ALL）患者在造血细胞移植（HCT）前通过多通道流式细胞术（MFC）检测出微小残留病（MRD）呈阳性，可识别出复发高危患者，但许多HCT前MFC-MRD阴性的患者也会复发，且HCT后早期MFC-MRD的预测能力较差。为了测试下一代测序 (NGS)-MRD 灵敏度的提高是否能更好地识别 HCT 前后的复发风险，我们对参加儿童肿瘤组试验 ASCT0431 的 56 名 B 细胞 ALL 患者进行了免疫球蛋白重链 (IgH) 可变、多样性和连接 (V[D]J) DNA 序列 J NGS-MRD。 NGS-MRD 比 MFC-MRD 更准确地预测复发和生存（P
Positive detection ofminimal residual disease (MRD) by multichannel flowcytometry (MFC) prior to hematopoietic cell transplantation (HCT) of patients with acute lymphoblastic leukemia (ALL) identifies patients at high risk for relapse, but many pre-HCT MFC-MRD negative patients also relapse, and the predictive power MFC-MRD early post-HCT is poor. To test whether the increased sensitivity of next-generation sequencing (NGS)-MRD better identifies pre- and post-HCT relapse risk, we performed immunoglobulin heavy chain (IgH) variable, diversity, and joining (V[D]J) DNA sequences J NGS-MRD on 56 patients with B-cell ALL enrolled in Children's Oncology Group trial ASCT0431. NGS-MRD predicted relapse and survival more accurately than MFC-MRD (P